Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

MLA

Yacoub, Abdulraheem, et al. “Phase 2 Study of Add-on Parsaclisib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Final Results.” Blood Advances, no. Preprints, Jan. 2024. EBSCOhost, https://doi.org/10.1182/bloodadvances.2023011620.

APA

Yacoub, A., Borate, U., Rampal, R. K., Ali, H., Wang, E. S., Gerds, A. T., Hobbs, G., Kremyanskaya, M., Winton, E., O, C. C., Goel, S., Oh, S. T., Schiller, G., McCloskey, J., Palmer, J., Holmes, H., Hager, S., Assad, A., Erickson-Viitanen, S., … Daver, N. (2024). Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Advances, Preprints. https://doi.org/10.1182/bloodadvances.2023011620

Chicago

Yacoub, Abdulraheem, Uma Borate, Raajit K. Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, et al. 2024. “Phase 2 Study of Add-on Parsaclisib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Final Results.” Blood Advances, no. Preprints (January). doi:10.1182/bloodadvances.2023011620.